FindTrial
Sign In

COMPARATIVE STUDY OF METHYL PHENYDATE VERSUS ATOMOXETINE IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER.

A STUDY ON COMPARATIVE EFFICACY OF METHYL PHENYDATE VERSUS ATOMOXETINE IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER - MPATADHD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/06/005853
Enrollment
140
Registered
2015-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Attention Deficit Hyperactivity Disorder

Interventions

Intervention1: METHYL PHENYDATE: 10mg twice daily for 3 months Control Intervention1: ATOMOXETINE: 40mg once daily for 3 months

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: patients diagnosed with ADHD and between age 6-12 years

Exclusion criteria

Exclusion criteria: patients below 6 and above 12 years of age and patients with eating or substance use disorder or mental retardation are excluded.

Design outcomes

Primary

MeasureTime frame
change in ADHD rating scale and CGI scale score before and after treatmentTimepoint: change in ADHD rating scale and CGI scale score before and after treatment—

Secondary

MeasureTime frame
to avaluate health related quality of life and medication adherence.Timepoint: baseline assessment after 3 months—

Countries

India

Contacts

Public Contactchithra v

medical college, thiruvananthapuram

drpamkunju@gmail.com9447246333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026